Facebook Twitter LinkedIn
February 17, 2026

Rhythm Biosciences (ASX:RHY): ColoSTAT comeback, with Genetype upside

Rhythm Biosciences (ASX:RHY) is a cancer diagnostics company. Since its listing, the Company has been focused on ColoSTAT, a blood test for colorectal cancer. While ColoSTAT is still a focus of Rhythm Biosciences, and the Company is in the early commercialisation phase, the late-2024 acquisition of Genetype could change investor perception entirely. GeneType offers further […]
Read More
MagSenseImagionIBX
February 10, 2026

Imagion Biosystems (ASX:IBX) is preparing for Phase 2

Imagion Biosystems (ASX: IBX) is the company behind MagSense, a revolutionary imaging agent. The company has just made an IND submission to the US FDA and plans to take MagSense into a Phase 2 clinical trial for HER2+ breast cancer once an answer from the regulator is received and this could be as early as Q1 in 2026. A $2bn TAM awaits The market for cancer diagnostics is a US$100bn market. […]
Read More
Green360 Technologies
GT3Green360
February 3, 2026

Green360 Technologies (ASX:GT3): In the low-carbon cement market with a big headstart

Green360 Technologies (ASX:GT3) is a building materials company. It is already a producer of kaolin but is also developing low-carbon and low-cost concrete technology. Already making money The company owns Australia’s only wet processing Kaolin Operation (Pittong in Victoria) where it is already generating revenue (>$25m over FY24 & FY25) from by selling several products […]
Read More
Amaero
3DAAmaero
January 21, 2026

Amaero (ASX:3DA) is helping to build the new Arsenal of Democracy

Amaero (ASX:3DA) is an emerging supplier of high-value refractory and titanium spherical powders including niobium C103 and Ti64, most of which are used in defence and aerospace applications. The company has also developed capability in parts manufacture. The company commissioned a commercial plant in Tennessee in 2024. Amaero aims to be the largest and lowest […]
Read More
Weebit Nano signs Texas Instruments
Weebit Nano
December 29, 2025

Weebit Nano (ASX:WBT) signs license deal with Texas Instruments, bags an elephant

Weebit Nano announced it has signed a licensing deal with Texas Instruments (TI), the world’s largest manufacturer of analog semiconductors, which are used in computer chips that deal with analog signals, such as temperature, pressure, sound etc. Analog semiconductors account for about 70% to 80% of TI’s revenues. TI also has an embedded processing division […]
Read More
PhosCo
PhosCoPHO
December 18, 2025

It’s all systems go for PhosCo (ASX:PHO) as it advances its Gasaat Phosphate Project in Tunisia

PhosCo (ASX:PHO) is advancing its Gasaat Phosphate Project in Tunisia with the support of government, local communities, and the European Bank for Reconstruction & Development. The company is well primed to become a cost-competitive, globally significant fertiliser producer, at a time of mounting supply concerns for phosphate, further underscored by its recent inclusion on the […]
Read More
Pharmaceutical Innovation
December 10, 2025

Dimerix Nears a Potential First-in-Class Approval in a High-Value Kidney Disease Market

Accelerated approval pathway for DMX-200 could reshape treatment for FSGS patients Dimerix Ltd (ASX: DXB) is entering what could be the most pivotal phase in its decade-long development journey for DMX-200 (Qytovra®), a drug targeting the rare and devastating kidney disease Focal Segmental Glomerulosclerosis (FSGS). With no approved treatments globally and only five years on […]
Read More
Percheron Therapeutics
Percheron TherapeuticsPER
November 27, 2025

Percheron Therapeutics (ASX:PER) has Phase 2 coming in 2026

Percheron Therapeutics (ASX:PER) has one of the most promising oncology assets in HMBD-002. HMBD-002 is an immune-oncology therapy (meaning it utilises a patient’s immune system) that inhibits a pathway called VISTA that plays a key role in suppressing T-cell responses to cancer treatments. Following positive Phase 1 data, Percheron is taking HMBD-002 into Phase 2 […]
Read More
Register for the Conference